Latest News and Press Releases

Liquidia Corporation (NASDAQ: LQDA) will present nine encore thematic posters at the 2024 Pulmonary Hypertension Association (PHA) International Conference

Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the second quarter ended June 30, 2024.

Liquidia Corporation to report second quarter 2024 financial results on August 7, 2024.

Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil)...

Judge Andrews denied the motion for preliminary injunction filed by United Therapeutics that sought to block the launch of Liquidia’s YUTREPIA™.

Liquidia Corporation's COO/CFO Michael Kaseta will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference in NYC.

Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024.

Liquidia Corporation (NASDAQ: LQDA) announced today the company will present data at the American Thoracic Society (ATS) 2024 International Conference.

Liquidia Corporation (NASDAQ: LQDA) announced today it will provide an update on the company at the BofA Securities Health Care Conference 2024.

Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2024 financial results on May 14, 2024.